Dawood Darbar, MD
Cardiovascular Disease · Chicago, ILNPI 1063596187
Payments from drug & device makers
What this record shows
The money is spread across several categories — travel and lodging (50.7%), speaking fees and food and beverage — rather than concentrated in one kind of arrangement. 9 manufacturers reported payments, led by Biotronik Inc. at 52.3% of the total. Among cardiovascular disease clinicians in IL with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 35 payments — averaging $637.13 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Biotronik Inc.$12K
- GE HealthCare$7K
- Altathera Pharmaceuticals LLC$2K
- Medtronic$913
- Boston Scientific$276
- Cardiovascular Systems Inc.$129
- plus $180 from 3 others
What the payments were for
- Consulting fees$1,8758%
- Speaking & faculty fees$7,15032%
- Travel & lodging$11,30051%
- Food & beverage$1,9759%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Biotronik Inc. | 5 | $11,665 |
| GE HealthCare | 2 | $7,150 |
| Altathera Pharmaceuticals LLC | 3 | $1,986 |
| Medtronic(2 entities) | 10 | $913 |
| Boston Scientific | 7 | $276 |
| Cardiovascular Systems Inc. | 2 | $129 |
| Cardiva Medical, Inc. | 1 | $101 |
| Abbott | 2 | $48 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 3 | $31 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$22,300 in reported general payments places this provider in the 90th percentile of 932 cardiovascular disease providers in Illinois.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 122 | $112,736 |
| XareltoRivaroxaban | 44 | $45,497 |
| Flecainide Acetate | 56 | $1,845 |
| Amiodarone Hcl | 27 | $1,309 |
| Metoprolol Succinate | 82 | $868 |
| Metoprolol Tartrate | 20 | $621 |
| Lisinopril | 12 | $94 |
| Carvedilol | 11 | $88 |
Paid to pharmacies, not to this prescriber.
Other cardiovascular disease in Chicago
- Sandeep NathanChicago$892K
- Boaz AvitallChicago$366K
- Akhil NarangChicago$363K
- Michael DavidsonChicago$317K
- Jyothy PuthumanaChicago$269K
- Sanjiv ShahChicago$246K
- Raja MutharasanChicago$146K
- Nitasha SarswatChicago$140K
- Evan SteinChicago$121K
- Dan FintelChicago$119K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.